Navigation Links
BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference
Date:1/8/2009

nd other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that our belief that many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular injection may not be correct, that HHS and the Food & Drug Administration (FDA) may not agree with our analysis, that HHS may further condition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future preclinical and clinical development may not have positive results, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not be able to retain its current phar
'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
5. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
6. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
9. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
10. BioCryst to Present at UBS 2008 Global Life Sciences Conference
11. BioCryst to Present at the JMP Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)...  Among 1,050 U.S. consumers, the majority knows little ... and only 36 percent reported being screened for oral ... from a survey released today by  Vigilant ... of solutions that aid in the early detection and ... 1,050 U.S. consumers on their knowledge of risk factors ...
(Date:4/1/2015)... YORK , April 1, 2015 ... advancing protein biologic therapies and oncology supportive care ... 2014 achievements and a strategic update for 2015. ... Company has made in the areas of business ... programs, the FDA clearance of the ProctiGard product, ...
(Date:4/1/2015)... YORK CITY and LONDON , ... market research reports and solutions, MarketResearch.com is pleased to highlight ... be a year of market growth and opportunity for the ... cell company or cord blood bank, competing in the stem ... conditions, predict industry trends, and act on market changes before ...
(Date:4/1/2015)... April 1, 2015 Immunocore ... novel biological drugs to treat cancer, viral infections ... the appointment of Christina Coughlin as ... for providing medical and regulatory leadership to the ... Dr. Coughlin has extensive experience in oncology ...
Breaking Biology Technology:National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 2National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 3National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 4PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 2PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 3PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 4PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 5PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 6MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 2MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 3MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 4Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 2Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 3Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 4
... Prepare your probe in less , ... Ideal for siRNA/miRNA studies , , ... activity RNA probes for RPA, Northern, Southern, or in situ hybridization , ... No cloning required , With the mir Vana miRNA ...
... Small Interfering RNAs (siRNAs) are , ... mRNAs for degradation via a cellular process termed RNA interference , ... have described , the use of ... knockdown studies (for a review, see Tuschl, 2002). Two different , ...
... , Low transfection efficiency is ... experiments. , We have found that by optimizing cell ... levels of transfection , efficiency can be achieved in ... Transfection is , Critical The ability of ...
Cached Biology Technology:Prepare siRNA and miRNA Probes in Just 1 Hour 2Prepare siRNA and miRNA Probes in Just 1 Hour 3More siRNA Vectors for RNA Interference 2More siRNA Vectors for RNA Interference 3More siRNA Vectors for RNA Interference 4More siRNA Vectors for RNA Interference 5More siRNA Vectors for RNA Interference 6More siRNA Vectors for RNA Interference 7Optimize Transfection of siRNAs for RNAi 2Optimize Transfection of siRNAs for RNAi 3Optimize Transfection of siRNAs for RNAi 4Optimize Transfection of siRNAs for RNAi 5Optimize Transfection of siRNAs for RNAi 6Optimize Transfection of siRNAs for RNAi 7Optimize Transfection of siRNAs for RNAi 8Optimize Transfection of siRNAs for RNAi 9Optimize Transfection of siRNAs for RNAi 10
(Date:3/23/2015)... March 23, 2015   HOYOS Labs , a ... today announced that the Company will demonstrate multiple biometrics-based ... and consumers at Connect:ID on March 23 through 25, ... Labs will highlight the IEEE Biometric Open Protocol Standard; ... and enterprise access control system. BOPS was invented by ...
(Date:3/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces its biometric ... the products featured in 2015 "I Want That" International ... EST on the DIY Network.   DIY,s ... , site of the 2015 International CES for ...
(Date:3/17/2015)... 2015 Emotient, the leader in facial ... general availability of Emotient Analytics , the ... of facial expressions. The system analyzes videos of ... and services. It delivers audience response metrics - ... as derived from facial evidence of emotional states. ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... Sainsbury Laboratory and the John Innes Centre will publish the first ... of disease. They will release the data via a ... system, called GitHub, was also used to crowdsource expertise during the ... around the world will be able to access the RNA sequence ...
... of Illinois at Urbana-Champaign has received a fiveyear, $5.7 million ... corn. These strains have the potential to combat the losses ... A team at the Institute for Genomic Biology in the ... the research. "Ozone can cause major damage and ...
... Since Edison,s first bulb, heat has been a mostly undesirable ... light into heat at the point of need, on the ... The method created by the Rice labs of Michael Wong, ... American Chemical Society journal ACS Nano makes use ...
Cached Biology News:Crowdsourcing to kickstart comeback from ash dieback 2University of Illinois receives grant to study ozone resistance in corn 2Rice uses light to remotely trigger biochemical reactions 2Rice uses light to remotely trigger biochemical reactions 3Rice uses light to remotely trigger biochemical reactions 4
Gentamicin sulfate, 5g...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
... Product Goat polyclonal to ... (Microorganism). Reactivity / Specificity Cross-reacts ... species. Background Information Cholesterol oxidases ... II oxidases and are implicated in bacterial ...
Rabbit polyclonal to SERHL ( Abpromise for all tested applications). entrezGeneID: 94009 SwissProtID: Q9H4I8...
Biology Products: